Prognosis and outcome of small (≤1 cm), node-negative breast cancer on the basis of hormonal and her-2 status

Surabhi Amar, Ann E. Mccullough, Winston Tan, Xochiquetzal J. Geiger, Judy C. Boughey, Rebecca B. McNeil, Kyle E. Coppola, Sarah A. Mclaughlin, Frances M. Palmieri, Edith A. Perez

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Long-term outcomes and hence the role of adjuvant therapy in patients with small (≤1 cm), node-negative breast cancer remain unclear. This study's objective was to evaluate whether human epidermal growth factor receptor (HER)-2 status is an independent, poor prognostic marker in patients with these tumors and to identify a subgroup of patients with these small tumors who might benefit from adjuvant systemic therapy. All patients with a diagnosis of a node-negative breast tumor measuring ≤1 cm and available HER-2 test results between January 1, 2001, and December 31, 2005, at the three Mayo Clinic sites were identified. Clinicopathologic data were compared in three groups: HER-2-, HER-2-, and triple-negative (TN) tumors. Of the 421 tumors identified, 364 (86.5%) were HER-2+, 28 (6.7%) were HER-2[1], and 29 (6.9%) were TN. The median follow-up time was 1,015 days (range, 1-2,549 days). Groups were balanced in terms of patient age and tumor histology. Eleven patients with HER-2 tumors (3.0%), seven with HER-2- tumors (25.0%), and eight with TN tumors (27.6%) received adjuvant chemotherapy. Follow-up data were available for 357, 28, and 28 patients in the three groups, respectively. Death rates in the three groups were 6.4% (23 of 357) (one recurrencerelated death), 0% (0 of 28), and 7.1% (2 of 28) (one recurrence-related death), respectively. During followup, the tumor recurred in nine patients: four were HER-2 tumors (1.1%), two were HER-2+ tumors (7.1%), and three were TN tumors (10.7%). Patients with small, node-negative breast tumors have an excellent prognosis, but HER-2+and TN tumors appear to have a higher recurrence rate, warranting consideration for broad use and optimization of systemic adjuvant treatments.

Original languageEnglish (US)
Pages (from-to)1043-1049
Number of pages7
Issue number10
StatePublished - Oct 2010


  • HER-2-positive tumor
  • Prognosis
  • Small breast cancer
  • Triple-negative tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prognosis and outcome of small (≤1 cm), node-negative breast cancer on the basis of hormonal and her-2 status'. Together they form a unique fingerprint.

Cite this